Experts Available for Interview•Robin N. Ginsburg, MD, Assistant Professor, Department of Ophthalmology, Mount Sinai Health System and Director of the Vitreoretinal Service, Mount Sinai Hospital •Richard B. Rosen, MD, FACS, Professor, Department of Ophthalmology, Mount Sinai Health System, Surgeon Director and Retina Service Chief, NYEE, and Director of Ophthalmology Research, NYEE
Facts about Age-Related Macular Degeneration (AMD)•The number of people living with any form of macular degeneration is similar to that of those who have been diagnosed with all types of invasive cancers.•As many as 11 million people in the United States have some form of AMD. This number is expected to double to by 2050.•AMD is the result of deterioration of a central area of the retina called the macula, which is the location of central vision. This deterioration can make vision become blurry or wavy. It can also result in a blind spot in the center of your vision.•Age is a major risk factor for developing AMD. Other risk factors include: a history of smoking; hypertension, and family history. AMD is more common among women and Caucasians but is seen among all races.•There are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type and in 10-20 percent of individuals, it progresses to the wet type.
Tips for Age-Related Macular Degeneration (AMD) Prevention and Treatment•If you have a family history of age-related macular degeneration (AMD), get a comprehensive dilated eye exam yearly after the age of 50. •AMD occurs less often in people who exercise, avoid smoking, and eat nutritious foods including green leafy vegetables and fish. If you already have AMD, adopting these habits may help you keep your vision longer.•Although some vision loss from AMD is irreversible, effective treatments can slow down progression or in some cases reverse vision deterioration.•Nutritional supplement formulations containing antioxidants and zinc (studied in the AREDS and AREDS2 clinical trials sponsored by the National Institutes of Health) have been shown to slow the disease in those who have intermediate AMD and those with advanced AMD in only one eye.•Anti-VEGF injections (medication specifically aimed at stopping the progression of the abnormal blood vessels that cause the vision loss) are an effective treatment for the wet or neovascular form of AMD and may control or reverse vision loss if administered shortly after the onset of vision loss. Early recognition of vision change, evaluation by an ophthalmologist, and starting proper medical treatment may be sight-saving. •Anti-Complement treatments and stem cell therapies are promising treatments for the advanced dry form of AMD, which are being studied at the Mount Sinai Health System. # # #
About the Mount Sinai Health System The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care. The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.
RSS